Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 261-270

  Xu, Rui ^a   Sato, Norihiro ^a   Yanai, Kosuke ^a   Akiyoshi, Takashi ^a   Nagai, Shuntaro ^a   Wada, Junji ^a   Koga, Kenichio ^a   Mibu, Ryuichi ^a   Nakamura, Masafumi ^a   Katano, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Apoptosis; Colon cancer; MAPK inhibition; Paclitaxel; PD98059

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CAMPTOTHECIN; FLUOROURACIL; HOE 33342; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA INTERFERENCE;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SYNERGISM; FLAVONOIDS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; PACLITAXEL; RNA, SMALL INTERFERING;

EID: 61449141236     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Chung KY and Saltz LB: Adjuvant therapy of colon cancer: current status and future directions. Cancer J 13: 192-197, 2007.
2. Monga DK and O'Connell MJ: Surgical adjuvant therapy for colorectal cancer: current approaches and future directions. Ann Surg Oncol 13: 1021-1034, 2006.
3. Wils J: Adjuvant treatment of colon cancer: past, present and future. J Chemother 19: 115-122, 2007.
4. Gorlick R and Bertino JR: Drug resistance in colon cancer. Semin Oncol 26: 606-611, 1999.
5. Einzig AI, Neuberg D, Wiernik PH, Grochow LB, Ramirez G, O'DwyerPJ and Petrelli NJ: Phase II: An Eastern Cooperative Oncology Group trial (PA286). Am J Ther 3: 750-754, 1996.
6. Rowinsky EK and Donehower RC: Paclitaxel (taxol). N Engl J Med 332: 1004-1014, 1995.
7. Orr GA, Verdier-Pinard P, McDaid H and Horwitz SB: Mechanisms of Taxol resistance related to microtubules. Oncogene 22: 7280-7295, 2003.
8. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ and Pu YS : Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65: 8455-8460, 2005.
9. Boldt S, Weidle UH and Kolch W: The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 23: 1831-1838, 2002.
10. MacKeigan JP, Collins TS and Ting JP: MEK inhibition enhancespaclitaxel- induced tumor apoptosis. J Biol Chem 275: 38953-38956, 2000.
11. McDaid HM and Horwitz SB: Selective potentiation of paclitaxel (taxol) -induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol 60: 290-301, 2001.
12. Yu C, Wang S, Dent P and Grant S: Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Mol Pharmacol 60: 143-154, 2001.
13. Seidman R, Gitelman I, Sagi O, Horwitz SB and Wolfson M: The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res 268: 84-92, 2001.
14. Kawaguchi W, Itamochi H, Kigawa J, Kanamori Y, Oishi T, Shimada M, Sato S, Shimogai R, Sato S and Terakawa N: Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma. Cancer Sci 98: 2002-2008, 2007.
15. Kuno Y, Kondo K, Iwata H, Senga T, Akiyama S, Ito K, Takagi H and Hamaguchi M: Tumor-specific activation of mitogen-activated protein kinase in human colorectal and gastric carcinoma tissues. Jpn J Cancer Res 59: 903-909, 1998.
16. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J and Kohno M: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822, 1999.
17. Akiyoshi T, Nakamura M, Yanai K, Nagai S, Wada J, Koga K, Nakashima H, Sato N, Tanaka M and Katano M: Gamma-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology 134: 131-144, 2008.
18. Sebolt-Leopold JS and Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947, 2004.
19. Kohno M and Pouyssegur J: Targeting the ERK signaling pathway in cancer therapy. Ann Med 38: 200-211, 2006.
20. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR and Saltiel AR: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810-816, 1999.
21. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung LY, Komarov AP, Keyomarsi K, Yarden Y and Seger R: Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20: 147-155, 2001.
22. Deng X, Ruvolo P, Carr B and May WS: Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA 97: 1578-1583, 2000.
23. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T and Murata Y: Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 60: 5988-5994, 2000.
24. Persons DL, Yazlovitskaya EM and Felling JC: Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 275: 35778-35785, 2000.
25. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J and Sugimoto Y: Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 6: 2092-2102, 2007.
26. Shafaee Z, Schmidt H, Du W, Posner M and Weichselbaum R: Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells. Cancer Chemother Pharmacol 58: 765-770, 2006.
27. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN and Beachy PA: Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425: 846-851, 2001.
28. Akiyoshi T, Nakamura M, Koga K, Nakashima H, Yao T, Tsuneyoshi M, Tanaka M and Katano M: Glil, down-regulated in colorectal cancers, inhibits proliferation of colon cancer cells involving Wnt signalling activation. Gut 55: 991-999, 2006.